Search...
/
The Fly Cast
Press play to listen
Competitive Advantages
Proprietary Drug Delivery Platform: DepoFoam technology provides extended-release of drugs, a unique and difficult-to-replicate system.
Dominant Market Position: Exparel holds a leading share in the post-surgical non-opioid pain management market.
Strong Intellectual Property Protection: Extensive patent coverage safeguards Exparel and the underlying DepoFoam technology.
Risks
Product Concentration Risk: Pacira's revenue is heavily reliant on sales of EXPAREL, making the company vulnerable to any issues affecting this single product's performance or market acceptance.
Competitive Landscape Risk: EXPAREL faces significant competition from a wide range of pain management therapies, including other long-acting local anesthetics, opioids, and non-opioid alternatives, potentially limiting market share and pricing power.
Regulatory and Compliance Risk: The company is subject to extensive and evolving healthcare laws and regulations, and any failure to comply with these, or delays in new product approvals or label expansions, could significantly impact operations and growth.
Wednesday
Over a week ago
May 28, 4:49 PM
May 27, 9:13 AM
May 26, 8:24 AM
May 20, 12:33 PM
May 13, 11:02 AM
May 1, 7:40 AM
Apr 30, 4:13 PM
Apr 30, 4:12 PM
Apr 13, 12:35 PM
Apr 13, 9:25 AM
Mar 26, 6:30 AM
Mar 11, 1:09 PM
Mar 6, 8:08 AM
Mar 2, 8:14 AM
Feb 26, 4:23 PM
Feb 26, 4:22 PM
Feb 12, 8:15 AM
Feb 9, 8:14 AM
Jan 13, 8:05 AM
Jan 12, 7:29 AM
